JP5425642B2 - 合成ｔｌｒアゴニストの結合体およびそのための使用 - Google Patents

合成ｔｌｒアゴニストの結合体およびそのための使用 Download PDF

Info

Publication number
JP5425642B2
JP5425642B2 JP2009549102A JP2009549102A JP5425642B2 JP 5425642 B2 JP5425642 B2 JP 5425642B2 JP 2009549102 A JP2009549102 A JP 2009549102A JP 2009549102 A JP2009549102 A JP 2009549102A JP 5425642 B2 JP5425642 B2 JP 5425642B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
aryl
alkoxy
tlr7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009549102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518082A5 (https=
JP2010518082A (ja
Inventor
デニス エー． カーソン，
ハワード ビー． コッタム，
ウォルフガング ラシドロ，
クリスティーナ シー． エヌ． ウー，
グレゴリー エー． ダニエルズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Los Angeles UCLA
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2010518082A publication Critical patent/JP2010518082A/ja
Publication of JP2010518082A5 publication Critical patent/JP2010518082A5/ja
Application granted granted Critical
Publication of JP5425642B2 publication Critical patent/JP5425642B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009549102A 2007-02-07 2008-02-07 合成ｔｌｒアゴニストの結合体およびそのための使用 Expired - Fee Related JP5425642B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88869907P 2007-02-07 2007-02-07
US60/888,699 2007-02-07
PCT/US2008/001631 WO2008115319A2 (en) 2007-02-07 2008-02-07 Conjugates of synthetic tlr agonists and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013059721A Division JP2013127004A (ja) 2007-02-07 2013-03-22 合成ｔｌｒアゴニストの結合体およびそのための使用

Publications (3)

Publication Number Publication Date
JP2010518082A JP2010518082A (ja) 2010-05-27
JP2010518082A5 JP2010518082A5 (https=) 2011-03-31
JP5425642B2 true JP5425642B2 (ja) 2014-02-26

Family

ID=39766655

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009549102A Expired - Fee Related JP5425642B2 (ja) 2007-02-07 2008-02-07 合成ｔｌｒアゴニストの結合体およびそのための使用
JP2013059721A Withdrawn JP2013127004A (ja) 2007-02-07 2013-03-22 合成ｔｌｒアゴニストの結合体およびそのための使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013059721A Withdrawn JP2013127004A (ja) 2007-02-07 2013-03-22 合成ｔｌｒアゴニストの結合体およびそのための使用

Country Status (17)

Country Link
US (3) US8357374B2 (https=)
EP (2) EP2510946B1 (https=)
JP (2) JP5425642B2 (https=)
KR (1) KR20090109121A (https=)
CN (1) CN101790380B (https=)
AU (1) AU2008227128B2 (https=)
CA (1) CA2677733A1 (https=)
DK (1) DK2510946T3 (https=)
EA (1) EA019151B1 (https=)
ES (2) ES2456964T3 (https=)
HU (1) HUE025555T2 (https=)
IL (1) IL200240A (https=)
PL (2) PL2125007T3 (https=)
PT (1) PT2510946E (https=)
SI (1) SI2510946T1 (https=)
WO (1) WO2008115319A2 (https=)
ZA (1) ZA200906094B (https=)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
EP2700638A1 (en) * 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
US20110014292A1 (en) * 2007-10-15 2011-01-20 Cooperative Research Centre For Asthma method of prophylaxis and agents for use therein
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
JP5694345B2 (ja) 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
AU2011247358B2 (en) * 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US20120003298A1 (en) * 2010-04-30 2012-01-05 Alcide Barberis Methods for inducing an immune response
JP2013525431A (ja) * 2010-04-30 2013-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成ｔｌｒ７アゴニストのリン脂質結合体の使用
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
EP2625292B1 (en) 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
PT3590928T (pt) 2011-04-08 2021-08-19 Janssen Sciences Ireland Unlimited Co Derivados de pirimidina para o tratamento de infeções virais
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
BR112013031039B1 (pt) * 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
EA035790B1 (ru) * 2012-07-13 2020-08-11 Янссен Сайенсиз Айрлэнд Юси Макроциклические пурины для лечения вирусных инфекций
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014052828A1 (en) 2012-09-27 2014-04-03 The Regents Of The University Of California Compositions and methods for modulating tlr4
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
CN111420045B (zh) * 2012-10-10 2023-03-31 深圳大学 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物
EA035431B1 (ru) 2012-11-16 2020-06-15 Янссен Сайенсиз Айрлэнд Юси Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций
SG11201506639XA (en) 2013-02-21 2015-09-29 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
JP6356160B2 (ja) * 2013-02-25 2018-07-11 ザ スクリプス リサーチ インスティテュート ネオセプチン：低分子アジュバント
JP6348967B2 (ja) * 2013-03-14 2018-06-27 ワン、ロンフ 制御性ｔ細胞機能を調節する方法および組成物
WO2014144365A1 (en) * 2013-03-15 2014-09-18 University Of Maryland, College Park Nano-liposomal formulations and methods of use
CN110590809B (zh) * 2013-03-29 2022-04-19 爱尔兰詹森科学公司 用于治疗病毒感染的大环脱氮-嘌呤酮
SG11201509520QA (en) 2013-05-24 2015-12-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
PT3030563T (pt) 2013-06-27 2017-11-15 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
DK3027624T3 (en) 2013-07-30 2019-01-07 Janssen Sciences Ireland Uc THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
EP3033089A2 (en) * 2013-08-16 2016-06-22 The Regents of The University of California Uses of phospholipid conjugates of synthetic tlr7 agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
DK3092256T3 (da) 2014-01-10 2022-06-20 Birdie Biopharmaceuticals Inc Forbindelser og sammensætninger til immunterapi
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
CN121243402A (zh) 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
ES2944541T3 (es) * 2014-08-06 2023-06-22 Scripps Research Inst Adyuvantes de molécula pequeña independientes de TLR
HRP20210927T1 (hr) * 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CA2973878A1 (en) 2015-01-22 2016-07-28 University Of Massachusetts Cancer immunotherapy
CA2986961C (en) 2015-05-26 2023-07-25 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
CN108139375A (zh) 2015-06-26 2018-06-08 贝斯以色列女执事医疗中心股份有限公司 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
CN108348618B (zh) * 2015-09-29 2021-06-15 大日本住友制药株式会社 腺嘌呤缀合物化合物及其作为疫苗佐剂的用途
CN105311032B (zh) * 2015-11-09 2018-09-25 深圳大学 Tlr7激动剂与酪氨酸激酶抑制剂联用在制备抗肿瘤药物中的应用
CN105315281B (zh) * 2015-11-16 2017-04-19 深圳大学 化合物i和化合物ii及其制备方法和应用
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
WO2017200957A1 (en) * 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
MA45539A (fr) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines pour le traitement d'infections virales
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
ES2912945T3 (es) 2016-09-29 2022-05-30 Janssen Sciences Ireland Unlimited Co Profármacos de pirimidina para el tratamiento de infecciones virales y otras enfermedades
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
JP7161760B2 (ja) * 2017-02-03 2022-10-27 国立大学法人東北大学 複素環化合物
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
US20200163880A1 (en) 2017-07-13 2020-05-28 Danmarks Tekniske Universitet Cationic liposomes
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN110317202B (zh) * 2018-03-30 2021-12-24 江苏恒瑞医药股份有限公司 氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
CN108379591B (zh) 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
WO2019197598A1 (en) * 2018-04-13 2019-10-17 Glaxosmithkline Biologicals Sa Tlr7 and / or tlr8 agonists
WO2019196918A1 (zh) * 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
CN112930184B (zh) * 2018-12-17 2024-07-12 卫材R&D管理有限公司 包含脂质体的配制品
CA3128386A1 (en) 2019-02-04 2020-08-13 Codiak Biosciences, Inc. Membrane protein scaffolds for exosome engineering
EP3908316A4 (en) * 2019-03-14 2023-03-29 The Regents Of The University Of California FORMULATIONS OF TLR4-TLR7 LIGANDS AS VACCINE ADJUVANTS
WO2020191305A2 (en) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
BR112021018694A2 (pt) 2019-03-21 2021-11-30 Codiak Biosciences Inc Vesículas extracelulares para distribuição de vacina
EP3941607A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
US20240108747A1 (en) 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
WO2021053163A1 (en) 2019-09-19 2021-03-25 Danmarks Tekniske Universitet Immune stimulating micelle composition
MX2022003570A (es) 2019-09-25 2022-07-11 Codiak Biosciences Inc Composiciones de vesícula extracelular.
JP7829485B2 (ja) * 2019-12-20 2026-03-13 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴｏｌｌ様受容体（「ＴＬＲ」）アゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
CN115135655B (zh) 2020-01-27 2024-07-02 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2021154661A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154667A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097104A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
EP4097105A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
WO2021154662A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115279765B (zh) 2020-01-27 2024-11-12 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
KR20220132601A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
EP4097100A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
EP4149550A4 (en) * 2020-05-15 2024-07-03 The Board of Trustees of the Leland Stanford Junior University TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
CN111892648B (zh) * 2020-06-08 2022-08-26 中国科学院上海药物研究所 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
JP2023532717A (ja) 2020-07-02 2023-07-31 ヴィーブ ヘルスケア カンパニー 長期作用型抗レトロウイルス剤を用いたｈｉｖウイルス寛解の達成方法
US20240082389A1 (en) 2020-09-23 2024-03-14 Lonza Sales Ag Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
JP2023546205A (ja) * 2020-10-21 2023-11-01 ユニヴェルザ ヴィ リュブリャナ コンジュゲートｔｌｒ７およびｎｏｄ２アゴニスト
WO2022200553A2 (en) 2021-03-25 2022-09-29 Danmarks Tekniske Universitet Immune stimulating nanoparticle composition
AU2021447099A1 (en) * 2021-05-27 2023-02-16 Cas Lamvac (Guangzhou) Biomedical Technology Co., Ltd. Method and kit for analyzing phenotype and function of CD303
KR20240109256A (ko) * 2021-11-03 2024-07-10 애드센트릭스 테라퓨틱스 잉크. 약물 접합체 및 이의 제조 및 사용 방법
CN116162088B (zh) * 2022-12-14 2025-03-11 江苏省农业科学院 一种Toll样受体7激动剂纳米颗粒及其制备方法与应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
DK0553202T3 (da) 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DE19637209B4 (de) 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
IL129319A0 (en) 1996-10-25 2000-02-17 Minnesota Mining & Mfg Immune response modifier compounds for treatment of TH2 mediated and related diseases
RU2177950C2 (ru) 1996-10-25 2002-01-10 Нексстар Фармасьютикалз, Инк. Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf)
JPH10298181A (ja) 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
CN1130363C (zh) 1997-11-12 2003-12-10 三菱化学株式会社 嘌呤衍生物以及含有其作为有效成分的药物
DE69817393T2 (de) 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
HU229441B1 (en) 1999-01-08 2013-12-30 3M Innovative Properties Co Formulations and methods for treating mucosal associated conditions with an immune response modifier
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
ATE327242T1 (de) 1999-12-17 2006-06-15 Ariad Pharma Inc Neue purine
DE60031886T2 (de) 1999-12-17 2007-09-06 Ariad Pharmaceuticals, Inc., Cambridge Purinderivate
IL150594A0 (en) 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
US6733764B2 (en) 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
AU1227302A (en) 2000-09-15 2002-03-26 Virco Nv System and method for optimizing drug therapy for the treatment of diseases
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
WO2002030399A2 (en) 2000-10-11 2002-04-18 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
EP2415486B1 (en) 2001-05-18 2017-02-22 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
DK1401837T3 (da) 2001-06-29 2005-11-07 Cv Therapeutics Inc Purinderivater som A2B-adenosinreceptorantagonister
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
GB0206461D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
MXPA05003193A (es) 2002-09-27 2005-06-08 Sumitomo Pharma Compuesto de adenina novedoso y uso del mismo.
JP2004137157A (ja) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
US20040202663A1 (en) 2003-01-28 2004-10-14 Shanghai Sunway Biotech Co., Ltd. Therapy for primary and metastatic cancers
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
MXPA06002997A (es) 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US20050266067A1 (en) 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
WO2005092892A1 (ja) * 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ８−オキソアデニン化合物
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
PT1819230E (pt) 2004-12-07 2012-08-07 Univ Miami Micropartículas derivadas de células vermelhas como agentes hemostáticos para o controlo da hemorragia e para o tratamento de patologias hemorrágicas
PL1879893T3 (pl) 2005-03-21 2010-11-30 Ferrer Int Sposób otrzymywania podstawionych w pozycji 1, związków 1H-imidazo[4,5-c]chinolino-4-aminowych i związki pośrednie
US20070292418A1 (en) 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
JPWO2007034817A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
WO2007038720A2 (en) 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of tlr-mediated immune responses using adaptor oligonucleotides
US20070100146A1 (en) 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
US20080008682A1 (en) 2006-07-07 2008-01-10 Chong Lee S Modulators of toll-like receptor 7
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7919490B2 (en) 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
WO2009052310A1 (en) 2007-10-16 2009-04-23 Cv Therapeutics, Inc A3 adenosine receptor antagonists
EA201001264A1 (ru) 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
JP5694345B2 (ja) 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
JP2013525431A (ja) 2010-04-30 2013-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成ｔｌｒ７アゴニストのリン脂質結合体の使用
AU2011247358B2 (en) 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
US20120003298A1 (en) 2010-04-30 2012-01-05 Alcide Barberis Methods for inducing an immune response
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators

Also Published As

Publication number Publication date
CN101790380B (zh) 2013-07-10
SI2510946T1 (sl) 2015-12-31
WO2008115319A2 (en) 2008-09-25
HUE025555T2 (en) 2016-02-29
US8790655B2 (en) 2014-07-29
HK1177886A1 (en) 2013-08-30
EP2510946B1 (en) 2015-08-05
IL200240A0 (en) 2010-04-29
WO2008115319A3 (en) 2009-03-05
JP2013127004A (ja) 2013-06-27
EP2125007A2 (en) 2009-12-02
CA2677733A1 (en) 2008-09-25
IL200240A (en) 2014-04-30
HK1138767A1 (en) 2010-09-03
PL2125007T3 (pl) 2014-07-31
KR20090109121A (ko) 2009-10-19
EA200901078A1 (ru) 2010-06-30
ES2456964T3 (es) 2014-04-24
PL2510946T3 (pl) 2015-12-31
BRPI0807196A2 (pt) 2014-06-03
ZA200906094B (en) 2011-12-28
ES2456964T9 (es) 2014-07-17
EP2125007B9 (en) 2014-04-16
ES2552471T3 (es) 2015-11-30
US8357374B2 (en) 2013-01-22
DK2510946T3 (en) 2015-11-02
US20130156807A1 (en) 2013-06-20
EP2510946A1 (en) 2012-10-17
AU2008227128B2 (en) 2012-12-06
US20120148660A1 (en) 2012-06-14
EA019151B1 (ru) 2014-01-30
PT2510946E (pt) 2015-11-23
EP2125007B1 (en) 2014-01-08
AU2008227128A1 (en) 2008-09-25
US20140302120A1 (en) 2014-10-09
CN101790380A (zh) 2010-07-28
US9050376B2 (en) 2015-06-09
JP2010518082A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
JP5425642B2 (ja) 合成ｔｌｒアゴニストの結合体およびそのための使用
AU2009210655B2 (en) Treatment of bladder diseases with a TLR7 activator
US20130202629A1 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
JP2013040209A (ja) Ｔｌｒアゴニスト
HK1177886B (en) Conjugates of synthetic tlr agonists and uses therefor
HK1138767B (en) Conjugates of synthetic tlr agonists and uses therefor
BRPI0807196B1 (pt) Compostos 6-amino-8-hidróxipurin-9-ilbenzil substituídos, e, usos dos mesmos
HK1126114A (en) Tlr agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131127

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees